Surrey Heartlands

Joint Formulary & PAD

Aflibercept - Myopic choroidal neovascularisation

You are here : Home > Formulary Search > Aflibercept - Myopic choroidal neovascularisation

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Intravitreal injection
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
ICB
NICE
Restrictions / Comments :

Documentation

Evidence Review
Aflibercept for treating choroidal neovascularisation - Briefing paper Jan 2018

PAD Profile

ChemicalSubstance :
Aflibercept
Indication :
Myopic choroidal neovascularisation
Group Name :
Keywords :
myopia, CNV
Brand Names Include :
Eylea
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Other Indications

Below are listed other indications that Aflibercept is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Myopic choroidal neovascularisation.

Committee Recommendations (1)

22 Jan 18 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Prescribing Clinical Network recommends aflibercept (Eylea) as a treatment option for choroidal neovascularisation in line with NICE TA486
Aflibercept is a payment by results excluded drug and will be considered RED on the traffic light system